Published in Ann Rheum Dis on January 18, 2008
Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol (2012) 3.79
Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet (2015) 3.38
IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice. J Clin Invest (2012) 2.64
A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis (2010) 2.22
Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis (2011) 1.93
The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res Ther (2008) 1.60
Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis (2012) 1.54
Mucocutaneous candidiasis: the IL-17 pathway and implications for targeted immunotherapy. Arthritis Res Ther (2012) 1.33
Use of biologics in rheumatoid arthritis: current and emerging paradigms of care. Clin Ther (2011) 1.29
Choice of Biologic Therapy for Patients with Rheumatoid Arthritis: The Infection Perspective. Curr Rheumatol Rev (2011) 1.23
Safety of biologic therapy in rheumatoid arthritis. Nat Rev Rheumatol (2011) 1.22
Risk of infections in bronchiectasis during disease-modifying treatment and biologics for rheumatic diseases. BMC Infect Dis (2011) 1.18
Proinflammatory role of vascular endothelial growth factor in the pathogenesis of rheumatoid arthritis: prospects for therapeutic intervention. Mediators Inflamm (2009) 1.14
B cells in the pathogenesis and treatment of rheumatoid arthritis. Curr Opin Rheumatol (2010) 1.13
Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders. Clin Exp Immunol (2009) 1.07
Post-stroke infection: a role for IL-1ra? Neurocrit Care (2011) 1.03
Abatacept treatment for rheumatoid arthritis. Rheumatology (Oxford) (2010) 1.03
Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment. Arthritis Res Ther (2010) 0.97
Infectious complications associated with monoclonal antibodies and related small molecules. Clin Microbiol Rev (2009) 0.96
Reactivation of chronic hepatitis B virus infection following rituximab administration for rheumatoid arthritis. Rheumatol Int (2009) 0.96
B cells as under-appreciated mediators of non-auto-immune inflammatory disease. Cytokine (2010) 0.93
Influenza and meningococcal vaccinations are effective in healthy subjects treated with the interleukin-1 beta-blocking antibody canakinumab: results of an open-label, parallel group, randomized, single-center study. Clin Vaccine Immunol (2010) 0.91
Rituximab for the treatment of rheumatoid arthritis: an update. Drug Des Devel Ther (2013) 0.91
An update on the pathology and clinical management of gouty arthritis. Clin Rheumatol (2011) 0.88
Rituximab for refractory granulomatous eye disease. Clin Ophthalmol (2012) 0.88
Long-term safety of subcutaneous abatacept in rheumatoid arthritis: integrated analysis of clinical trial data representing more than four years of treatment. Arthritis Rheumatol (2014) 0.88
The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis. Ann Rheum Dis (2015) 0.86
New insights into the impact of neuro-inflammation in rheumatoid arthritis. Front Neurosci (2014) 0.86
Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials. Arthritis Res Ther (2015) 0.85
The influence of ageing on the development and management of rheumatoid arthritis. Nat Rev Rheumatol (2013) 0.85
Are Th17 cells an appropriate new target in the treatment of rheumatoid arthritis? Clin Transl Sci (2010) 0.81
Immune regulators of inflammation in obesity-associated type 2 diabetes and coronary artery disease. Curr Opin Endocrinol Diabetes Obes (2014) 0.81
Efficacy and safety of rituximab in rheumatic diseases. Wien Med Wochenschr (2015) 0.81
Transglutaminase 2 cross-linking activity is linked to invadopodia formation and cartilage breakdown in arthritis. Arthritis Res Ther (2012) 0.80
Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug Effectiveness Review Project. Biologics (2009) 0.80
Indications of rituximab in autoimmune diseases. Drug Discov Today Ther Strateg (2009) 0.80
Selective delivery of interleukine-1 receptor antagonist to inflamed joint by albumin fusion. BMC Biotechnol (2012) 0.79
Severe alcoholic hepatitis-current concepts, diagnosis and treatment options. World J Hepatol (2014) 0.79
Translating co-stimulation blockade into clinical practice. Arthritis Res Ther (2008) 0.79
Evaluation of abatacept in biologic-naïve patients with active rheumatoid arthritis. Clin Rheumatol (2010) 0.79
The discovery of novel experimental therapies for inflammatory arthritis. Mediators Inflamm (2010) 0.79
IL-1 Receptor Antagonist Treatment Aggravates Staphylococcal Septic Arthritis and Sepsis in Mice. PLoS One (2015) 0.79
Characterization of the MMP/TIMP Imbalance and Collagen Production Induced by IL-1β or TNF-α Release from Human Hepatic Stellate Cells. PLoS One (2016) 0.79
May anakinra be used earlier in adult onset Still disease? Clin Rheumatol (2010) 0.78
Assessing infection risk with biologic agents in RA: methodological challenges. Nat Rev Rheumatol (2009) 0.78
[Infectious complications of biologic therapy in patients with rheumatoid arthritis]. Z Rheumatol (2010) 0.78
The risk of infections in hematologic patients treated with rituximab is not influenced by cumulative rituximab dosage - a single center experience. BMC Infect Dis (2014) 0.77
Rationale of using different biological therapies in rheumatoid arthritis. Arthritis Res Ther (2010) 0.77
Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies. Int J Rheum Dis (2016) 0.77
[Anti-CD20 therapy in rheumatoid arthritis]. Z Rheumatol (2009) 0.77
[Recommedations for the use of abatacept in patients with rheumatoid arthritis]. Z Rheumatol (2008) 0.77
[A novel treatment option in rheumatoid arthritis: abatacept, a selective modulator of T-cell co-stimulation]. Wien Med Wochenschr (2009) 0.76
Functions of interleukin-34 and its emerging association with rheumatoid arthritis. Immunology (2016) 0.76
Regulation of Transforming Growth Factor β-Activated Kinase Activation by Epigallocatechin-3-Gallate in Rheumatoid Arthritis Synovial Fibroblasts: Suppression of K(63) -Linked Autoubiquitination of Tumor Necrosis Factor Receptor-Associated Factor 6. Arthritis Rheumatol (2016) 0.76
The Interleukin-1 Balance During Encephalitis Is Associated With Clinical Severity, Blood-Brain Barrier Permeability, Neuroimaging Changes, and Disease Outcome. J Infect Dis (2015) 0.76
Biologic therapies and infections in the daily practice of three Italian rheumatologic units: a prospective, observational study. Clin Rheumatol (2016) 0.76
Identification of cytomegalovirus and human herpesvirus-6 DNA in a patient with corneal endotheliitis. Jpn J Ophthalmol (2012) 0.76
Targeting the B cell in vasculitis. Pediatr Nephrol (2008) 0.75
Both anti-TNF and CTLA4 Ig treatments attenuate the disease severity of staphylococcal dermatitis in mice. PLoS One (2017) 0.75
Vasculitis syndromes: Inducing remission in ANCA-positive vasculitis: time to RAVE? Nat Rev Rheumatol (2010) 0.75
Interleukin-1 antagonists in the treatment of autoinflammatory syndromes, including cryopyrin-associated periodic syndrome. Open Access Rheumatol (2011) 0.75
Comparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: A multicenter retrospective cohort study in Japan. PLoS One (2017) 0.75
Update on the use of rituximab for intractable rheumatoid arthritis. Open Access Rheumatol (2009) 0.75
The efficacy and safety of abatacept in rheumatoid arthritis. Ther Adv Musculoskelet Dis (2010) 0.75
Efficacy, safety, and tolerability of abatacept in the management of rheumatoid arthritis. Open Access Rheumatol (2009) 0.75
Nocardiosis in a patient with rheumatoid arthritis treated with rituximab and a summary of reported cases. BMJ Case Rep (2010) 0.75
The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis. Arthritis Res Ther (2016) 0.75
Rituximab for Rheumatoid Arthritis. Rheumatol Ther (2015) 0.75
[Recommendations for use of abatacept in patients with rheumatoid arthritis]. Z Rheumatol (2014) 0.75
A randomised, placebo-controlled trial of anti-interleukin-1 receptor 1 monoclonal antibody MEDI8968 in chronic obstructive pulmonary disease. Respir Res (2017) 0.75
A Case of Schnitzler's Syndrome without Monoclonal Gammopathy-Associated Chronic Urticaria Treated with Anakinra. Yonsei Med J (2018) 0.75
[Secondary immunodeficiency in rheumatological diseases]. Z Rheumatol (2013) 0.75
Do antiepileptic drugs increase the risk of infectious diseases? A meta-analysis of placebo-controlled studies. Br J Clin Pharmacol (2017) 0.75
[Screening investigations during intensified immunosuppression in children and adolescents. Part 1]. Z Rheumatol (2013) 0.75
The effect of infliximab on antiviral antibody profiles in patients with rheumatoid arthritis. Rheumatol Int (2009) 0.75
[Medicinal prophylaxis during intensified immunosuppression in children and adolescents : part 2]. Z Rheumatol (2013) 0.75
[Risk of infection by biologics]. Z Rheumatol (2008) 0.75
Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry. Clin Rheumatol (2017) 0.75
The Therapeutic Role of Interleukin-1 Inhibition in Idiopathic Recurrent Pericarditis: Current Evidence and Future Challenges. Front Med (Lausanne) (2017) 0.75
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum (1988) 111.05
Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med (2001) 18.25
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med (2000) 16.20
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med (2004) 14.53
A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med (1999) 11.62
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum (2006) 8.78
Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med (1999) 6.84
Bias in location and selection of studies. BMJ (1998) 6.47
Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis (2004) 6.45
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med (2005) 6.37
The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum (2006) 5.68
What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med (2004) 5.67
Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med (2006) 5.03
Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum (2002) 4.69
Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med (2003) 4.67
Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum (2005) 4.64
Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum (1998) 4.37
Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2002) 3.78
Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology (Oxford) (2003) 3.70
Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis (2004) 3.64
Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum (2005) 3.64
Predictors of infection in rheumatoid arthritis. Arthritis Rheum (2002) 3.47
Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum (2004) 3.06
Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis (2004) 2.68
Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum (2002) 2.44
Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. Arthritis Rheum (2006) 1.96
Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol (2001) 1.86
Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis (2006) 1.74
Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial. Arthritis Rheum (2003) 1.64
The safety of anakinra in high-risk patients with active rheumatoid arthritis: six-month observations of patients with comorbid conditions. Arthritis Rheum (2004) 1.61
Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum (2003) 1.58
A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis (2004) 1.53
Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists. Arthritis Rheum (2004) 1.25
Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatology (Oxford) (2006) 1.22
Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis. J Rheumatol (2004) 0.90
Adverse events in patients with rheumatoid arthritis treated with infliximab in daily clinical practice. Ann Rheum Dis (2005) 0.88
OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage (2008) 10.99
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis (2009) 8.37
EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis (2003) 7.95
OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage (2010) 7.52
The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis (2010) 5.24
Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III. J Rheumatol (1997) 5.09
EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis (2004) 4.94
EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis (2006) 4.83
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis (2011) 4.78
Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum (2001) 4.57
The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis (2009) 4.37
EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis (2000) 4.37
OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage (2007) 4.34
ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis (2005) 4.31
OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthritis Cartilage (2004) 4.01
Evaluation of clinically relevant changes in patient reported outcomes in knee and hip osteoarthritis: the minimal clinically important improvement. Ann Rheum Dis (2004) 3.95
Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis (2004) 3.64
Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis (2002) 3.53
Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis (2003) 3.33
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis (2009) 3.32
Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis (2007) 3.31
Design and conduct of clinical trials in patients with osteoarthritis: recommendations from a task force of the Osteoarthritis Research Society. Results from a workshop. Osteoarthritis Cartilage (1996) 3.26
Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis (2008) 3.17
[Criteria of the classification of spondylarthropathies]. Rev Rhum Mal Osteoartic (1990) 3.04
International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis (2003) 2.85
European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis (2011) 2.74
Synovitis: a potential predictive factor of structural progression of medial tibiofemoral knee osteoarthritis -- results of a 1 year longitudinal arthroscopic study in 422 patients. Osteoarthritis Cartilage (2005) 2.69
Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis (2006) 2.68
Evaluation of clinically relevant states in patient reported outcomes in knee and hip osteoarthritis: the patient acceptable symptom state. Ann Rheum Dis (2004) 2.60
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis (2008) 2.55
Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis (2003) 2.48
Management of osteoarthritis (OA) with an unsupervised home based exercise programme and/or patient administered assessment tools. A cluster randomised controlled trial with a 2x2 factorial design. Ann Rheum Dis (2004) 2.29
The role of pain and functional impairment in the decision to recommend total joint replacement in hip and knee osteoarthritis: an international cross-sectional study of 1909 patients. Report of the OARSI-OMERACT Task Force on total joint replacement. Osteoarthritis Cartilage (2010) 2.24
New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis (2009) 2.22
Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol (1999) 2.21
First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis (2005) 2.21
Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group. Assessments in Ankylosing Spondylitis. J Rheumatol (1999) 2.12
Preliminary core sets for endpoints in ankylosing spondylitis. Assessments in Ankylosing Spondylitis Working Group. J Rheumatol (1997) 2.11
EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis (2010) 2.09
Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis (2006) 2.07
Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis (2004) 2.06
Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Ann Rheum Dis (2002) 2.02
Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis (2007) 2.01
Prognostic factors for radiographic damage in early rheumatoid arthritis: a multiparameter prospective study. Arthritis Rheum (2001) 2.00
Predictive factors for the longterm outcome of spondyloarthropathies. J Rheumatol (1994) 1.99
Finalisation and validation of the rheumatoid arthritis impact of disease score, a patient-derived composite measure of impact of rheumatoid arthritis: a EULAR initiative. Ann Rheum Dis (2011) 1.97
Efficacy and safety of opioids for osteoarthritis: a meta-analysis of randomized controlled trials. Osteoarthritis Cartilage (2007) 1.91
Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Ann Rheum Dis (2009) 1.90
Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis (2008) 1.84
Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis (2013) 1.81
Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis (2005) 1.77
Challenges of cardiovascular risk assessment in the routine rheumatology outpatient setting: an observational study of 110 rheumatoid arthritis patients. Arthritis Care Res (Hoboken) (2013) 1.76
Individual smallest detectable difference in bone mineral density measurements. J Bone Miner Res (1999) 1.74
Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis (2006) 1.71
Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis (2005) 1.70
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Arthritis Rheum (2008) 1.66
European League Against Rheumatism recommendations for the inclusion of patient representatives in scientific projects. Ann Rheum Dis (2011) 1.59
Sensitivity and specificity of the American College of Rheumatology 1987 criteria for the diagnosis of rheumatoid arthritis according to disease duration: a systematic literature review and meta-analysis. Ann Rheum Dis (2008) 1.59
Effects of joint lavage and steroid injection in patients with osteoarthritis of the knee: results of a multicenter, randomized, controlled trial. Arthritis Rheum (1999) 1.57
Reporting of patient-reported outcomes in recent trials in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis (2008) 1.57
Diagnostic features of ankylosing spondylitis. Br J Rheumatol (1995) 1.56
Arthroscopic evaluation of chondropathy in osteoarthritis of the knee. J Rheumatol (1996) 1.55
Phenotypic diversity is not determined by independent genetic factors in familial spondylarthropathy. Arthritis Rheum (2001) 1.52
Defining disease activity in ankylosing spondylitis: is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument? Rheumatology (Oxford) (1999) 1.51
The role of HLA genes in familial spondyloarthropathy: a comprehensive study of 70 multiplex families. Ann Rheum Dis (2002) 1.51
The familial form of spondylarthropathy: a clinical study of 115 multiplex families. Groupe Français d'Etude Génétique des Spondylarthropathies. Arthritis Rheum (2000) 1.51
Efficacy of thalidomide in the treatment of refractory ankylosing spondylitis. Arthritis Rheum (1999) 1.47
Clinical and ultrasonographic predictors of joint replacement for knee osteoarthritis: results from a large, 3-year, prospective EULAR study. Ann Rheum Dis (2009) 1.47
Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum (2010) 1.47
EULAR report on the use of ultrasonography in painful knee osteoarthritis. Part 1: prevalence of inflammation in osteoarthritis. Ann Rheum Dis (2005) 1.44
Laterally elevated wedged insoles in the treatment of medial knee osteoarthritis. A two-year prospective randomized controlled study. Osteoarthritis Cartilage (2004) 1.44
Radiological medical joint space narrowing and meniscal lesions. Steering Committee of French Society of Arthroscopy. Br J Rheumatol (1995) 1.43
Minimum clinically important improvement and patient acceptable symptom state in pain and function in rheumatoid arthritis, ankylosing spondylitis, chronic back pain, hand osteoarthritis, and hip and knee osteoarthritis: Results from a prospective multinational study. Arthritis Care Res (Hoboken) (2012) 1.40
A comparative study of the usefulness of the Bath Ankylosing Spondylitis Functional Index and the Dougados Functional Index in the assessment of ankylosing spondylitis. J Rheumatol (1999) 1.40
Arthroscopic evaluation of potential structure modifying activity of hyaluronan (Hyalgan) in osteoarthritis of the knee. Osteoarthritis Cartilage (1997) 1.38
Ankylosing spondylitis: plenary discussion and results of voting on selection of domains and some specific instruments. J Rheumatol (1999) 1.36
Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann Rheum Dis (2005) 1.35
Efficacy and safety of steroid injections for shoulder and elbow tendonitis: a meta-analysis of randomised controlled trials. Ann Rheum Dis (2008) 1.35
The development of a short measure of physical function for hip OA HOOS-Physical Function Shortform (HOOS-PS): an OARSI/OMERACT initiative. Osteoarthritis Cartilage (2008) 1.35
Long term structural effects of combination therapy in patients with early rheumatoid arthritis: five year follow up of a prospective double blind controlled study. Ann Rheum Dis (2003) 1.32
Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: a EULAR initiative. Ann Rheum Dis (2008) 1.32
Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine. Ann Rheum Dis (2008) 1.32
Metabolic bone assessment in patients with inflammatory bowel disease. Gastroenterology (1995) 1.31
Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries. Ann Rheum Dis (2003) 1.31
Radiological scoring methods in ankylosing spondylitis: reliability and sensitivity to change over one year. J Rheumatol (1999) 1.31
Association between radiographic damage of the spine and spinal mobility for individual patients with ankylosing spondylitis: can assessment of spinal mobility be a proxy for radiographic evaluation? Ann Rheum Dis (2005) 1.30
OARSI-OMERACT definition of relevant radiological progression in hip/knee osteoarthritis. Osteoarthritis Cartilage (2009) 1.30
Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor alpha. Ann Rheum Dis (2003) 1.30
Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study. Ann Rheum Dis (2004) 1.29
Comparative evaluation of three semi-quantitative radiographic grading techniques for knee osteoarthritis in terms of validity and reproducibility in 1759 X-rays: report of the OARSI-OMERACT task force. Osteoarthritis Cartilage (2008) 1.28
Low bone mineral density in patients with inflammatory bowel disease. Dig Dis Sci (1992) 1.28
The development of a short measure of physical function for knee OA KOOS-Physical Function Shortform (KOOS-PS) - an OARSI/OMERACT initiative. Osteoarthritis Cartilage (2008) 1.28